Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation

被引：0
|
作者：
Brunner, Andrew M. [1 ]
Blonquist, Traci M. [2 ]
McMasters, Malgorzata [3 ]
Hobbs, Gabriela S. [4 ]
McAfee, Steven L. [4 ]
Rosenblatt, Jacalyn [3 ]
Amrein, Philip C. [4 ]
Connolly, Christine [4 ]
Ramos, Aura Y. [4 ]
Mikami, Kaleb [3 ]
Logan, Emma [3 ]
Dey, Bimalangshu R. [4 ]
Spitzer, Thomas [4 ]
Avigan, David E. [3 ]
Chen, Yi-Bin [5 ]
Ballen, Karen K. [6 ]
El-Jawahri, Areej [4 ]
Fathi, Amir T. [5 ]
机构：
[1] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[6] Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110559
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4587
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapsing after allogeneic hematopoietic cell transplantation (HCT).
    Chiattone, A.
    Andersson, B.
    Bashir, Q.
    Landau, D.
    Rondon, G.
    Nieto, Y.
    Al Atrash, G.
    Giralt, S.
    Champlin, R. E.
    De Lima, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Mixed chimerism after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    de Lima, M
    Carrasco, A
    Lee, MS
    Saliba, R
    Glassman, A
    Anagnostopoulos, A
    Couriel, D
    Caldera, H
    Andersson, BS
    El-Zimaity, M
    Giralt, S
    Champlin, R
    BLOOD, 2003, 102 (11) : 707A - 707A
  • [3] Prognostic factors for allogeneic stem cell transplantation (ASCT) for refractory acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS).
    Wong, R
    Shahjahan, M
    De Lima, M
    Anagnostopoulos, A
    Estey, E
    Champlin, R
    Andersson, B
    Khouri, I
    Giralt, S
    BLOOD, 2002, 100 (11) : 853A - 853A
  • [4] Phase I Study of Bortezomib Combined with Lenalidomide for Relapsed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Following Hematopoietic Cell Transplantation
    Brunner, Andrew M.
    Blonquist, Traci M.
    McMasters, Malgorzata
    Hobbs, Gabriela S.
    McAfee, Steven L.
    Rosenblatt, Jacalyn
    Amrein, Philip C.
    El-Jawahri, Areej
    Connolly, Christine
    Ramos, Aura
    Mikami, Kaleb
    Logan, Emma
    Dey, Bimalangshu R.
    Spitzer, Thomas
    Avigan, David E.
    Fathi, Amir T.
    Chen, Yi-Bin
    Ballen, Karen
    BLOOD, 2017, 130
  • [5] Dose reduced conditioning and allogeneic stem cell transplantation in 34 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Bornhauser, M
    Kroschinsky, F
    Ulrike, S
    Markus, S
    Eberhard, S
    Ralph, N
    Thiede, C
    Ulrich, S
    Gerhard, E
    BLOOD, 2000, 96 (11) : 780A - 780A
  • [6] Dose reduced conditioning and allogeneic stem cell transplantation in 36 patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
    Bornhäuser, M
    Schaich, M
    Schaekel, U
    Mahlberg, R
    Clemens, M
    Ehninger, G
    BONE MARROW TRANSPLANTATION, 2001, 27 : S85 - S85
  • [7] Acute myeloid leukemia (AML) and Myelodysplastic syndrome (MDS) associated with Monosomy 7: Management by allogeneic hematopoietic stem cell transplantation (HSCT)
    Giller, RH
    Trobaugh, AD
    Hunger, SP
    Malcolm, J
    Schissel, D
    Hild, E
    Quinones, RR
    PEDIATRIC RESEARCH, 2002, 51 (04) : 251A - 251A
  • [8] Trends in hospitalization outcomes of elderly patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia/myelodysplastic syndrome (AML/MDS).
    Murthy, Guru Subramanian Guru
    Mehta, Paulette
    Jethava, Yogesh
    Dhakal, Ishwori
    Makhoul, Issam
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Allogeneic haematopoietic stem cell transplantation for elderly patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): A single center analysis
    Katayama, Y.
    Iwato, K.
    Ohchi, T.
    Okatani, T.
    Imanaka, R.
    Kyo, K.
    Itagaki, M.
    Katsutani, S.
    Kyo, T.
    Asaoku, H.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S475 - S476
  • [10] Prognostic factors for allogeneic stem cell transplantation (ASCT) for untreated first relapse of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS)
    Alamo, JG
    Shahjahan, M
    Wong, RS
    de Lima, M
    Khouri, I
    Gajewski, J
    Couriel, D
    Andersson, BS
    Anderlini, P
    Champlin, R
    Giralt, S
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 38 - 39
12345